Advancing breakthroughs in neuroscience to elevate life.
Elevating Lives for More Than 30 Years
For more than three decades, Acadia has been at the forefront of healthcare, elevating lives by providing essential solutions to those who need them most. We pioneered the first and only approved therapies for hallucinations and delusions in Parkinson’s disease psychosis and Rett syndrome. Currently, our clinical-stage developments focus on addressing negative symptoms in schizophrenia, Prader-Willi syndrome, Alzheimer’s disease psychosis, and neuropsychiatric symptoms in CNS disorders.
Innovative therapies for Parkinson’s and Rett syndrome
Advancing treatments for schizophrenia and Alzheimer’s
Committed to addressing unmet needs in rare diseases
Fighting Disease So More “You” Shines Through
At Acadia, we are committed to developing therapies in areas with high unmet needs, elevating life to ensure a brighter future for all. United in our commitment, we strive for a healthier tomorrow—embracing diverse perspectives, fostering collaboration, and standing resilient in our mission to elevate life with unwavering dedication.
Latest Perspectives from Acadia
On Rare Disease Day, Helping Rare Shine Through
Rare Disease Day is observed every year on February 28 (or 29 in leap years)—the rarest day of the year. Since its creation in 2008, Rare Disease Day has been uniting a diverse, global community around one purpose: To change and improve the lives of individuals living with a rare disease.
We help patients fight their diseases not only with therapies, but with support, education and connection.
We have FDA-approved treatments for Parkinson’s Disease Psychosis and Rett syndrome.
We are a community of unique individuals with the mindset of a scientist, dedication of a healthcare provider and heart of a caregiver.